Journal of the American Society of Hypertension
Volume 2, Issue 3 , Pages 182-191 , May 2008

Endothelin contributes differently to peripheral vascular tone and blood pressure in human obesity and diabetes

  • Nancy Yoon, MD

      Affiliations

    • Indiana University, Indianapolis, Indiana, USA
    • ,
  • Amale A. Lteif, MD

      Affiliations

    • Indiana University, Indianapolis, Indiana, USA
    • ,
  • KyungAh Han, MD

      Affiliations

    • Eulji University, Seoul, Korea
    • ,
  • Kieren J. Mather, MD, FRCPC

      Affiliations

    • Indiana University, Indianapolis, Indiana, USA
    • Corresponding Author InformationCorresponding author: Kieren J. Mather, MD, FRCPC, Division of Endocrinology and Metabolism, Department of Medicine, Indiana University School of Medicine, 975 West Walnut Street, IB424, Indianapolis, Indiana 46202. Tel: 317-278-7826; fax: 317-274-2695.

Received 3 August 2007 ,Accepted 10 October 2007.

References 

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:2560–2572
  2. Dornfeld LP, Maxwell MH, Waks A, Tuck M. Mechanisms of hypertension in obesity. Kidney Int Suppl. 1987;22:S254–S258
  3. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep. 2000;2:139–147
  4. Hall JE, Louis K. Dahl Memorial Lecture (Renal and cardiovascular mechanisms of hypertension in obesity). Hypertension. 1994;23:381–394
  5. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension. 2004;43:36–40
  6. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004;53:2060–2066
  7. Cardillo C, Kilcoyne CM, Cannon RO, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension. 2000;35:1237–1241
  8. Levin ER. Endothelins. N Engl J Med. 1995;333:356–363
  9. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999;33:753–758
  10. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signaling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365:1817–1820
  11. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction (Implications for the syndrome of insulin resistance). J Clin Invest. 1996;97:2601–2610
  12. Katakam PV, Pollock JS, Pollock DM, Ujhelyi MR, Miller AW. Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistant rats. Am J Physiol Heart Circ Physiol. 2001;280:H522–H527
  13. Nava P, Guarner V, Posadas R, Perez I, Banos G. Insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats. Am J Physiol. 1999;277:H399–H404
  14. Sainani GS, Maru VG, Mehra AP. Role of endothelin-1 in genesis of coronary artery disease. Indian Heart J. 2005;57:121–127
  15. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes. 2002;51:3517–3523
  16. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes. 2007;56:728–734
  17. Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J. Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care. 2007;30:591–596
  18. Sarafidis PA, Bakris GL. Insulin and endothelin: an interplay contributing to hypertension development?. (review) J Clin Endocrinol Metab. 2007;92:379–385
  19. Francischetti EA, Genelhu VA. Obesity-hypertension: an ongoing pandemic. Int J Clin Pract. 2007;61:269–280
  20. Han KA, Lteif AA, Mather KJ. Blood pressure response to type A endothelin receptor antagonism in human obesity and diabetes mellitus. J Hum Hypertens. 2006;20:798–800
  21. Paradisi G, Smith L, Burtner C, Leaming R, Garvey WT, Hook G, et al. Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care. 1999;22:1310–1317
  22. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783–1787
  23. Veniant M, Clozel JP, Hess P, Clozel M. Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. Life Sci. 1994;55:445–454
  24. Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860–1870
  25. Schiffrin EL. Endothelin in hypertension. Curr Opin Cardiol. 1995;10:485–494
  26. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96:1593–1597
  27. Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens. 1996;14:57–64
  28. Cardillo C, Campia U, Kilcoyne CM, Bryant MB, Panza JA. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation. 2002;105:452–456
  29. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension (Bosentan Hypertension Investigators). N Engl J Med. 1998;338:784–790
  30. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation. 1997;96:4104–4113
  31. Baron AD, Brechtel G, Johnson A, Fineberg N, Henry DP, Steinberg HO. Interactions between insulin and norepinephrine on blood pressure and insulin sensitivity (Studies in lean and obese men). J Clin Invest. 1994;93:2453–2462
  32. Gaboury CL, Simonson DC, Seely EW, Hollenberg NK, Williams GH. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest. 1994;94:2295–2300
  33. Wofford MR, Hall JE. Pathophysiology and treatment of obesity hypertension. Curr Pharm Des. 2004;10:3621–3637
  34. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270–1277
  35. Hall JE, Brands MW, Zappe DH, Alonso-Galicia M. Cardiovascular actions of insulin: are they important in long-term blood pressure regulation?. Clin Exp Pharmacol Physiol. 1995;22:689–700
  36. DeFronzo RA, Ferrannini E. Insulin resistance (A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease). Diabetes Care. 1991;14:173–194
  37. Ferri C, Bellini C, Desideri G, Baldoncini R, Properzi G, Santucci A, et al. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes. 1997;105:S38–S40
  38. Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T, et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem. 1991;266:23251–23256
  39. Wolpert HA, Steen SN, Istfan NW, Simonson DC. Insulin modulates circulating endothelin-1 levels in humans. Metabolism. 1993;42:1027–1030
  40. Ahlborg G, Weitzberg E, Lundberg JM. Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans. J Appl Physiol. 1995;79:141–145
  41. Rizzoni D, Porteri E, Piccoli A, Castellano M, Bettoni G, Pasini G, et al. The vasoconstriction induced by endothelin-1 is mediated only by ET(A) receptors in mesenteric small resistance arteries of spontaneously hypertensive rats and Wistar Kyoto rats. J Hypertens. 1997;15:1653–1657
  42. Bohm F, Pernow J, Lindstrom J, Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond). 2003;104:143–151
  43. Lee RM, Owens GK, Scott-Burden T, Head RJ, Mulvany MJ, Schiffrin EL. Pathophysiology of smooth muscle in hypertension. Can J Physiol Pharmacol. 1995;73:574–584
  44. da Silva AA, Kuo JJ, Tallam LS, Hall JE. Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension. Hypertension. 2004;43:383–387
  45. Iglarz M, Matrougui K, Levy BI, Henrion D. Chronic blockade of endothelin ETA receptors improves flow dependent dilation in resistance arteries of hypertensive rats. Cardiovasc Res. 1998;39:657–664
  46. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997–1001
  47. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353–355
  48. De Mattia G, Cassone-Faldetta M, Bellini C, Bravi MC, Laurenti O, Baldoncini R, et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens. 1998;11:983–988
  49. Benigni A, Perico N, Remuzzi G. Endothelin antagonists and renal protection. J Cardiovasc Pharmacol. 2000;35:S75–S78
  50. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): observational study. BMJ. 2000;321:412–419
  51. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–B64

 This project was supported by an award from the American Diabetes Association (7-02-JF-30) to Dr. Mather and the Indiana University General Clinical Research Center (NIH M01 RR00750).

 Conflict of interest: none.

PII: S1933-1711(07)00205-7

doi: 10.1016/j.jash.2007.10.006

Journal of the American Society of Hypertension
Volume 2, Issue 3 , Pages 182-191 , May 2008

Article Tools

* Image Usage & Resolution